Loading...
XNAS
ARCT
Market cap193mUSD
Dec 05, Last price  
7.13USD
1D
4.39%
1Q
-60.06%
Jan 2017
-51.50%
IPO
-1.11%
Name

Arcturus Therapeutics Holdings Inc

Chart & Performance

D1W1MN
XNAS:ARCT chart
P/E
—
P/S
1.40
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.47%
Rev. gr., 5y
46.10%
Revenues
138m
-12.27%
00006,138,00020,382,00012,998,00015,753,00020,789,0009,539,00012,359,000205,755,000157,748,000138,389,000
Net income
-81m
L+172.30%
-3,929,000-1,579,000-10,548,000-32,834,000-19,449,000-24,603,000-10,902,000-21,785,000-25,721,000-71,364,000-206,863,0009,349,000-29,725,000-80,941,000
CFO
-60m
L+230.11%
-2,361,000-1,585,000-7,353,000-28,326,000-18,148,000-19,241,000-460,000-20,760,000-6,445,000-42,861,000-135,043,00031,993,000-18,099,000-59,747,000
Dividend
Jan 04, 20130.0085 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
URL
https://arcturusrx.com/
IPO date
May 22, 2013
Employees
170
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT